A method for the treatment and/or prophylaxis of cerebrovascular disorders and/or disorders associated with cerebral senility in mammals, such as humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a compound of formula (I): ##STR1## wherein (i) R.sub.1 is a group --X--CO--CH.sub.3 where X is a hydrocarbon radical having up to 4 carbon atoms which may be substituted by a methyl group, R.sub.2 and R.sub.3, which may be the same or different, each represents a straight-chain or branched-chain alkyl radical of 2 to 6 carbon atoms, or a cyclohexyl, alkoxyalkyl or hydroxyalkyl radical, and Y and Z each represent oxygen; (ii) R.sub.1 is a group --CH.sub.2 (OR.sub.4)(OR.sub.5)CH.sub.3 wherein R.sub.4 is an alkyl radical of 1 to 4 carbon atoms and R.sub.5 is an alkyl radical of 1 to 4 carbon atoms or R.sub.4 is linked to R.sub.5 so that the OR.sub.4 and OR.sub.5 moieties and the carbon atoms to which they are attached form a 1,3-dioxacylohexa-2,2-diyl,1,3-dioxacyclopenta-2, 2-diyl or 1,3-dioxacyclohepta-2,2-diyl diradical, R.sub.2 and R.sub.3 are the same or different and are each an alkyl radical of 1 to 4 carbon atoms, and Y and Z each represent oxygen; (iii) R.sub.1 is a group --CH.sub.2 COCH.sub.3, R.sub.2 is an alkyl radical of 1 to 6 carbon atoms, R.sub.3 is an alkyl radical of 1 to 6 carbon atoms, Z is sulphur and Y is oxygen or sulphur; (iv) R.sub.1 is a group --(CH.sub.2).sub.n COCH.sub.3 where n is 1 or 2, one of R.sub.2 and R.sub.3 is an alkyl radical of 1 to 6 carbon atoms and the other is an alkyl radical of 2 to 6 carbon atoms, Z is oxygen and Y is sulphur; or (v) R.sub.1 is a group --CH.sub.2 COCH.sub.3, R.sub.2 is an alkyl radical of 1 to 4 carbon atoms, R.sub.3 is a group CH.sub.3 CO(CH.sub.2).sub.4 --, and Y and Z each represent oxygen.
Compounds of the formula ##STR1## as defined in the specification, and processes for their preparation and methods of using the compounds for the treatment of hypertension in mammals, such as humans and for the treatment and/or prophylaxis of cerebrovascular disorders and/or disorders associated with cerebral senility in mammals, such as humans.
A compound of formula (I): ##STR1## or where appropriate a pharmaceutically acceptable salt thereof, wherein R.sup.1 and R.sup.2 each independently represent a moiety of formula (a): wherein m represents zero or an integer 1, 2 or 3, A represents a substituted or unsubstituted cyclic hydrocarbon radical; and R.sup.3 represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or a moiety of formula (a) as defined above; a pharmaceutical composition comprising such a compound a process for preparing such a compound and the use of said compound and said composition in medicine.
Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula ##STR1## wherein R.sup.1 and R.sup.3 are the same or different and are each (C.sub.1 -C.sub.8)alkyl, ##STR2## R.sup.2 is (C.sub.1 -C.sub.4)alkyl; R.sup.4 and R.sup.5 are the same or different and are each hydrogen or (C.sub.1 -C.sub.2)alkyl; R.sup.6 is (C.sub.1 -C.sub.2)alkyl; and m, n and p are the same or different and are each 1, 2, 3, 4, 5 or 6; with the proviso that one of the groups R.sup.1 and R.sup.3 is ##STR3## or that R.sup.3 represents ##STR4## Some of the compounds of formula I are novel.
A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. The inhibition of Il-1, TNF, and other cytokines in mammals is implicated in allerviation of a wide variety of disease conditions.
5096906 - Method of inhibiting the activity of leukocyte derived cytokines - Owned by University of Virginia Alumni Patents Foundation (Charlottesville, VA) Hoechst Roussel Pharmaceuticals Inc. (Somerville, NJ) [*] Notice:The portion of the term of this patent subsequent to October 23, 2007 has been disclaimed.
A family of compounds effective in inhibiting interleukin-1 (IL-1) activity, tumor necrosis factor (TNF) activity, and the activity of other leukocyte derived cytokines is comprised of 7-(oxoalkyl) 1,3-dialkyl xanthines of the formula ##STR1## in which R.sub.1 and R.sub.2 are the same or different and are selected from the group consisting of straight-chain or branched alkyl radicals with 2 to 6 carbon atoms, cyclohexyl, alkoxyalkyl and hydroxyalkyl radicals, and A represents a hydrocarbon radical with up to 4 carbon atoms which can be substituted by a methyl group. Another family of effective compounds is identified as ##STR2## The inhibition of IL-1, TNF, and other cytokines in mammals is implicated in alleviation of a wide variety of disease conditions.
